Trials / Recruiting
RecruitingNCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TACE with adebrelimab and bevacizumab | TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days); |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2026-11-15
- Completion
- 2026-11-15
- First posted
- 2023-08-01
- Last updated
- 2024-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05970666. Inclusion in this directory is not an endorsement.